Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis.
Hideaki TsujiRan NakashimaYuji HosonoYoshitaka ImuraMasato YagitaHajime YoshifujiShintaro HirataTakaki NojimaEiji SugiyamaKazuhiro HattaYoshio TaguchiMasaki KatayamaKiminobu TanizawaTomohiro HandaRyuji UozumiShuji AkizukiKosaku MurakamiMotomu HashimotoMasao TanakaKoichiro OhmuraTsuneyo MimoriPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
A combined immunosuppressive regimen is effective for anti-MDA-5-positive DM patients with ILD. Plasmapheresis can be used for additional effect in intractable disease. Patients should be carefully monitored for opportunistic infections during treatment.
Keyphrases
- high dose
- end stage renal disease
- low dose
- interstitial lung disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- genome wide
- clinical trial
- systemic lupus erythematosus
- adipose tissue
- disease activity
- breast cancer cells
- cross sectional
- signaling pathway
- cell therapy
- idiopathic pulmonary fibrosis
- patient reported
- insulin resistance